all investments current investments previous investments


Bind Therapeutics (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles.


Biomaterials and bioactives for chronic wounds and bone regeneration.


Molecular Partners is developing a novel class of binding proteins (DARPins) that will compete with monoclonal antibodies by addressing some of their weaknesses.


Drug develpment company focused on the new therapies for immune-related disorders and inflammation.
 


Indication for pulmonary arterial hypertension (PAH), a life-threatening disorder which severely compromises the function of the lungs and heart. IPO on SWX in April 2000.


Founded in April 2000. Discovery and development of small molecules active on novel G protein-coupled receptors. CHF38 Mio raised, 60 employees. Most advanced project (Phase II): sub-arachnoid haemorrhage. Acquired by Actelion (ATLN) in October 2003.


Discovery and development of SGDs (small glycan drugs) to provide the patient with safer and more efficient anti-thrombotics.


Flamentera is developing monitoring tests for celiac disease


Lumavita is a biotech-pharma company based in Basel, Switzerland, specialising in Woman’s Health.


Neocutis is a spin-off from the CHUV hospital in Lausanne, focused on innovative dermatology, skin care, wound healing treatment and cosmetics.


Mid-stage specialty pharmaceutical company in dental market. The Novalar product (a vasodilatator), rapidly reverses the lingering and debilitating lip and tongue numbness associated with local dental anesthesia.


OncoEthix is a drug development company dedicated to the development of compounds in oncology.


Indications of stroke and the related indications neuronal damage and thrombotic disease. IPO on Frankfurt exchange (PA8) in February 2005.
 


Indication for pulmonary arterial hypertension (PAH), a life-threatening disorder which severely compromises the function of the lungs and heart. IPO on SWX in April 2000.


Founded in April 2000. Discovery and development of small molecules active on novel G protein-coupled receptors. CHF38 Mio raised, 60 employees. Most advanced project (Phase II): sub-arachnoid haemorrhage. Acquired by Actelion (ATLN) in October 2003.


Bind Therapeutics (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles.


Discovery and development of SGDs (small glycan drugs) to provide the patient with safer and more efficient anti-thrombotics.


Flamentera is developing monitoring tests for celiac disease


Biomaterials and bioactives for chronic wounds and bone regeneration.


Lumavita is a biotech-pharma company based in Basel, Switzerland, specialising in Woman’s Health.


Molecular Partners is developing a novel class of binding proteins (DARPins) that will compete with monoclonal antibodies by addressing some of their weaknesses.


Neocutis is a spin-off from the CHUV hospital in Lausanne, focused on innovative dermatology, skin care, wound healing treatment and cosmetics.


Mid-stage specialty pharmaceutical company in dental market. The Novalar product (a vasodilatator), rapidly reverses the lingering and debilitating lip and tongue numbness associated with local dental anesthesia.


Drug develpment company focused on the new therapies for immune-related disorders and inflammation.


OncoEthix is a drug development company dedicated to the development of compounds in oncology.


Indications of stroke and the related indications neuronal damage and thrombotic disease. IPO on Frankfurt exchange (PA8) in February 2005.
  
© Endeavour Vision SA 2006-2017 Terms & Conditions